Key result
The PL-12 analyzer effectively predicted adverse clinical outcomes in acute cerebral infarction patients treated with aspirin, yielding an AUC of 0.748, which was superior to thromboelastography and the platelet count drop method.
Why the study?
Does the PL-12 analyzer improve the prediction of clinical outcomes in patients with acute cerebral infarction on aspirin therapy compared to TEG and platelet count drop methods?
Observational (n=370)
No
Does the PL-12 analyzer improve the prediction of clinical outcomes in patients with acute cerebral infarction on aspirin therapy compared to TEG and platelet count drop methods?
The automated PL-12 analyzer provides superior predictive value for 12-month clinical outcomes in acute cerebral infarction patients on aspirin compared to traditional thromboelastography and platelet count drop methods.
Answers are grounded in this paper and cite their sources.
May enhance risk stratification in aspirin-treated acute stroke; leaves open prospective validation before practice change.
METHODS: All participants were administered with oral aspirin (100 mg/d) for 7 days. Blood samples were then collected and platelet function evaluated by an automated PL-12 analyzer, TEG, and the platelet count drop method. We found that platelet counts determined by the traditional platelet drop method were significantly lower in the PL-12 sensitive group and significantly higher in the PL-12 insensitive group (P < 0.05). Furthermore, MAR measured by PL-12 was positively correlated with the MA values determined by TEG and the platelet drop method (r = 0.322, r = 0.036, respectively, P < 0.05), More importantly, the PL-12 analyzer showed the largest AUC (0.748) with a sensitivity of 87.4% and a specificity of 57.4%, indicating PL-12 analyzer using in platelet aggregation evaluation of ACI patients more credibly and accuracy. Additionally, genetic analysis showed that the polymorphic of A-allele in the PEAR1 (rs12041331) gene was significantly increased in the PL-12 sensitive group rather than in the PL-12 insensitive group (P < 0.05), suggesting the predictive value of PL-12 analyzer for the prognosis of ACI patients was superior to the other methods tested herein. Our analyses demonstrate that PL-12 analysis offer a new superior technology for monitoring antiplatelet drug efficacy and for clinical prognosis of ACI patients, which has the advantages of simplicity, speed, and automation in platelet aggregation measurement.
No takes yet. Share an insight, caveat, or question.
Yue et al. (2021) conducted an observational in Acute cerebral infarction (n=370). PL-12 analyzer vs. Thromboelastography (TEG) and platelet count drop method was evaluated on Prediction of end-point events (cerebral infarction recurrence, bleeding, or death) at 12 months (AUC 0.748, 95% CI 0.704-0.792, p=<0.001). The PL-12 analyzer effectively predicted adverse clinical outcomes in acute cerebral infarction patients treated with aspirin, yielding an AUC of 0.748, which was superior to thromboelastography and the platelet count drop method.
Synapse has enriched 10 related papers. Consider them for comparative context: